Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma

David Stahl; Martin Braun; Andrew J. Gentles; Philipp Lingohr; Adeline Walter; Glen Kristiansen; Ines Gütgemann

doi:10.18632/oncotarget.19357

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma

David Stahl, Martin Braun, Andrew J. Gentles, Philipp Lingohr, Adeline Walter, Glen Kristiansen and Ines Gütgemann _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:76329-76339. https://doi.org/10.18632/oncotarget.19357

Metrics: PDF 1552 views | HTML 3575 views | ?

Abstract

David Stahl1, Martin Braun1, Andrew J. Gentles2, Philipp Lingohr3, Adeline Walter4, Glen Kristiansen1 and Ines Gütgemann1

1Institute of Pathology, University Hospital Bonn, Bonn, Germany

2Center for Cancer Systems Biology (CCSB), Stanford University, Stanford, California, USA

3Department of General, Visceral, Thoracic and Vascular Surgery, University Hospital Bonn, Bonn, Germany

4Department of Gynecology and Obstetrics, University Hospital Bonn, Bonn, Germany

Correspondence to:

Ines Gütgemann, email: [email protected]

Keywords: BUB1, immunohistochemistry, biomarker, gastric adenocarcinoma, gastric cancer

Received: March 17, 2017 Accepted: June 19, 2017 Published: July 18, 2017

ABSTRACT

Gastric adenocarcinomas are associated with a poor prognosis due to the fact that the tumor has often metastasized by the time of diagnosis and prognostic markers are urgently needed to tailor treatment.

We examined the expression of the mitotic spindle checkpoint protein BUB1 (budding uninhibited by benzimidazoles 1) and Ki-67 protein expression by immunohistochemistry in 218 patients with primary gastric adenocarcinomas.

Tumors with low frequency of BUB1 expression were associated with larger tumor size (pT) (p < 0.001), higher incidence of lymph node metastases (pN) (p = 0.027), distant metastases (pM) (p = 0.006) and higher UICC stage (p < 0.001). Furthermore, BUB1 expression was inversely correlated with residual tumor stage (p = 0.038). Abundant BUB1 protein expression correlated with frequent Ki-67 protein expression (p < 0.001) and low BUB1 expression was associated with shorter survival (p < 0.001). Univariate and multivariate analyses confirmed BUB1 to be an independent prognostic marker in gastric cancer (p = 0.021).

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19357

Publication Alerts

Research Papers:

Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma

Abstract